NYSE: ELVElevance Health Inc Stock
$406.69-17.84 (-4.2%)
Updated Apr 21, 2025
ELV Price
$406.69
Fair Value Price
N/A
Market Cap
$92.46B
52 Week Low
$362.21
52 Week High
$567.26
P/E
15.76x
P/B
2.24x
P/S
0.48x
PEG
0.78x
Dividend Yield
1.62%
Revenue
$177.01B
Earnings
$5.98B
Gross Margin
16.8%
Operating Margin
5.14%
Profit Margin
3.4%
Debt to Equity
1.83
Operating Cash Flow
$6B
Beta
0.54
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ELV's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Healthcare Plan
Industry Rating
A
ELV
Ranked#3 of 10
Ranked#3 of 10
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $324.77 | B | |
| $58.01 | B | |
| $425.33 | B |
Be the first to know about important ELV news, forecast changes, insider trades & much more!
ELV News
Overview
Due Diligence Score
–
Industry Average (41)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ELV scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ELV ($406.69) is trading above its intrinsic value of $319.99, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ELV is good value based on its earnings relative to its share price (15.76x), compared to the US market average (27.14x)
P/E vs Market Valuation
ELV is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more ELV due diligence checks available for Premium users.
Valuation
ELV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
15.76x
Industry
23.44x
Market
27.14x
ELV is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ELV is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ELV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.24x
Industry
2.47x
ELV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ELV price to earnings growth (PEG)
For valuing profitable companies with growth potential
ELV is good value based... subscribe to Premium to read more.
PEG Value Valuation
ELV's financial health
Profit margin
Revenue
$45.4B
Net Income
$418.0M
Profit Margin
0.9%
ELV's Earnings (EBIT) of $9.10B... subscribe to Premium to read more.
Interest Coverage Financials
ELV's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$116.9B
Liabilities
$75.5B
Debt to equity
1.83
ELV's short-term assets ($58.94B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ELV's short-term assets ($58.94B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ELV's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ELV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$706.0M
Investing
-$1.6B
Financing
$1.4B
ELV's operating cash flow ($5.81B)... subscribe to Premium to read more.
Debt Coverage Financials
ELV vs Healthcare Plan Stocks
Elevance Health Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.